RU2281113C1 - Agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza - Google Patents

Abstract

FIELD: medicine, in particular agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza.

SUBSTANCE: claimed agent contains physiological saline for intravenous administration, comprising hydrogen peroxide, 0.2 % riboxine solution and decoction of liquorice roots in specific ratio.

EFFECT: non-toxic and effective agent for treatment of abovementioned diseases.

7 ex

Description

The invention relates to medicine, in particular to agents for the treatment of hepatitis, or toxoplasmosis, or cytomegalovirus infection, or influenza.

There is a method of treating chronic hepatitis by introducing a patient Sinapara, prednisone, hydrocortisone. (Chronic hepatitis. Discussion (transcript of discussion at the "Round Table") - "Therapeutic Archive", 1982, No. 12, p.123-124).

However, with the known method, the treatment of patients is long - up to 6-7 months, and sometimes even longer, while prolonged severe forms of liver inflammation often turn into cirrhosis.

Known from the patent literature is a method of treating liver cirrhosis in surgery using an infusate, which includes 200 ml of aminosteril-N-hep, 200 ml of a 20-30% glucose solution, 15-20 ml of a 5-10% ascorbic acid solution 10-15 ml. Riboxinum, 50 ml of a 20% solution of albumin and 2 ml of heparcomposite. Such an infusion is performed within 3-5 days for 2-3 hours daily (see US Pat. RF No. 2165775, IPC A 61 K 38/00, publ. 04/27/2002).

There is a method of treating viral hepatitis using pathogenetic therapy, including prodigiosan, thymalin, pyrogenal, splenin, decaris and T-activin (Cherednichenko TV 2nd All-Union Congress of Infectious Diseases. Tashkent: Medicine, 1981, p. 292-294).

At the same time, treatment of patients with viral hepatitis with pyrogenal and prodigiosan often leads to increased hepatocytolysis, manifested by intoxication, temperature reaction, hepatomegaly, increased jaundice and AlAT enzymes.

The use of thymalin in the relief of exacerbations and prolonged convalescence in viral hepatitis is also doubtful. Great difficulties arise in assessing the effectiveness of splenin in the treatment of viral hepatitis, since this drug was used in the initial stage of the disease. The appointment of levamisole to patients with viral hepatitis cannot be considered justified, because it often contributes to an increase in ALAT and HBS AR titers in HBV. It is believed that levamisole indirectly causes increased lysis of infected hepatocytes. Its repeated use at a dose of 2 mg / kg causes serious and even potentially life-threatening adverse reactions of a hematological and non-hematological nature.

A method for the treatment of viral hepatitis with T-activin requires further research and generalizations.

In the available literature there is no information about drugs and methods of treatment of toxoplasmosis.

A known method of treating cytomegalovirus infection in women with habitual miscarriage, including the use of chemotherapeutic agents: ganciclovir (cymevene), foscarnet, acyclovir. However, it has the following disadvantages: firstly, these drugs are usually used for cytomegalovirus infection in patients with HIV infection and have side effects: nausea, vomiting, diarrhea, headache, itching, rash, leukopenia, neutropenia, anemia, thrombocytopenia, deposits in bone marrow (foscarnet), which subsequently may adversely affect the general status of the woman, the course of her ongoing pregnancy and the condition of the fetus. The route of administration is usually intravenous. During treatment with acyclovir, quite pronounced resistance to cytomegalovirus was noted.

A known method of treating cytomegalovirus infection in women with habitual miscarriage, comprising exposure to immunostimulants (decaris, T-activin). However, this method has the following disadvantages: itching, leukopenia, agranulocytosis, thrombocytopenia, nausea, vomiting, and inadequate accounting of the state of the immune system (see Dadalyan L.G. Obstetric management of women with habitual miscarriage, complicated by cytomegalovirus infection. Collection of scientific works. Prevention, diagnosis and treatment of women with miscarriage and the provision of medical care to their children. - M., 1990, pp. 99-102).

In domestic and world medical practice, only two are currently used as influenza drugs - amantadine and its closest structural analogue, remantadine. (Romanov Yu.A. et al. Chemoprophylaxis of influenza with amantadine. L., 1971, p. 220-230).

However, these drugs are inactive in the treatment of type B flu. They are toxic. Their use in people is accompanied by side effects of these drugs on the central nervous system (insomnia, headache. Decreased concentration, vomiting). In addition, the widespread use of remantadine and amantadine for the treatment of patients with influenza A has led to the emergence of a strain of influenza viruses that are resistant to these chemotherapy drugs.

Influenza A and B viruses significantly differ from each other in antigenic and biological properties. Therefore, the antiviral activity of the drug used to treat influenza A does not suggest the possibility of its use in influenza B. The exception is Arbidol (see Pat. RF No. 20088004, IPC A 61 K 31/405, bull. No. 4, 1994 )

The objective of the invention is to expand the arsenal of means of exposure to a living organism, namely the development of a drug for the treatment of hepatitis, or toxoplasmosis, or cytomegalovirus infection, or influenza.

The problem is solved by the use of agents for the treatment of hepatitis, or toxoplasmosis, or cytomegalovirus infection, or flu, which is a physiological solution for intravenous administration containing hydrogen peroxide, 0.2% Riboxin solution and a decoction of licorice roots in the following ratio of ingredients, ml / l:

Hydrogen peroxide 0.6-1.25 Riboxin 25.0-50.0 Licorice root broth 5.0-10.0 Saline Up to 1000

The values of the components of the funds listed above are optimal to achieve the maximum therapeutic effect.

If you take hydrogen peroxide less than 0.6 ml / l, 0.2% Riboxin solution less than 25.0 ml / l and a decoction of licorice roots less than 5.0 ml / l per 1000 ml of physiological solution, then the therapeutic effect is not achieved . This is confirmed by the enzyme-linked immunosorbent assay, proving that such a concentration of the drug does not change the titers of antibodies, immunoglobulins in the blood.

If you take hydrogen peroxide more than 1.25 ml / l, 0.2% Riboxinum solution more than 50.0 ml / l and a decoction of licorice roots more than 10.0 ml / l per 1000 ml of saline, then as a result of intravenous administration of the drug, fibrosis is observed vessels. This is confirmed by experimental studies on volunteers.

The above statements indicate a causal relationship between the amount of each component of the product with the achieved technical result (therapeutic effect).

The quantitative content of the components of the tool is selected empirically.

In practical medicine, a solution of hydrogen peroxide (3%) is used as a disinfectant and deodorizing agent for rinsing and rinsing with stomatitis, tonsillitis, gynecological diseases, etc. (Mashkovsky M.D. Medicines, part II. M .: Medicine. 1978 , p. 340-341). It is a clear, colorless, odorless liquid or with a faint peculiar odor, slightly acid reaction. It quickly decomposes in the light, when heated, in contact with alkali, oxidizing and reducing substances, releasing oxygen.

Based on a large number of laboratory and clinical studies, it was found that by intravenous infusion of hydrogen peroxide, bacterial, fungal, parasitic and viral infections can be successfully combated, as well as stimulate the immune system and inhibit the growth of tumors. However, it is noted that during infusions, the peroxide solution should not be mixed with other drugs (see W. Douglas. The healing properties of hydrogen peroxide. St. Petersburg: Peter, 1998, p. 179).

Licorice root, in medical practice, is used as an expectorant (tincture). From the roots and rhizomes of licorice receive a number of drugs "Liquiriton" granules "Flacartin" with anti-inflammatory activity. (Mashkovsky M.D. Medicines. Part I., M .: Medicine. S.325-326).

Riboxin is administered intravenously, stimulates the heart muscle; used in practice as a psychotropic agent. Riboxin, being a nucleoside, can penetrate into cells and increase the energy balance of the myocardium. There is evidence of the ability of Riboxin to increase the activity of a number of enzymes, stimulate nucleotide synthesis, exert a positive effect on metabolic processes in the myocardium and improve coronary circulation. A drug is also prescribed for liver diseases; there is evidence of an improvement in visual function in patients with glaucoma (see Mashkovsky MD Medicines. Vol. II, M .: New Wave LLC. 2002. p.165).

For the first time, it was proposed to use an intravenous mixture of hydrogen peroxide, decoction of licorice roots and riboxin as a means for treating a number of diseases: hepatitis, or toxoplasmosis, or cytomegalovirus infection, or flu.

Licorice decoction is prepared from dry crushed licorice rhizome. Based on 10 g per liter of distilled water. Boil for 5-8 minutes over low heat, infused until the broth is cooled. It is filtered through a coarse, then a medical filter, poured into bottles of 30-50 ml, sterilized at a temperature of 100 ° C for 30 minutes. The broth is stored at a temperature of 2-4 ° C for 8 months.

Composition 1.

To get 1 liter of a working (main) solution of the claimed drug, you need to take hydrogen peroxide 0.6 ml, plus 0.2% solution of riboxin 25.0 ml, decoction of licorice roots 5.0 ml and add 969.4 ml of standard saline.

Composition 2

To get 1 liter of the working (main) solution of the claimed drug, you need to take 0.975 ml of hydrogen peroxide, plus a 0.2% solution of riboxin 37.5 ml, a decoction of licorice roots 7.5 ml and add 954.025 ml of standard saline.

Composition 3.

To get 1 liter of the working (main) solution of the claimed drug, you need to take hydrogen peroxide 1.25 ml, plus 0.2% solution of riboxin 50.0 ml, decoction of licorice roots 10.0 ml and add 938.75 ml of standard saline.

The drug was prepared by simply mixing the components before introducing into the vein of the patient. The drug is administered intravenously multiple times in direct proportion to the severity of the disease. Treatment is carried out in courses of 10-20 infusions, at a rate of 40-60 drops per minute, after 3-4 days.

The invention is illustrated by the following examples of the treatment of diseases in volunteers.

Example 1. Free Solyakov I., born in 1963 Diagnosis: Hepatitis B. The course of treatment of the proposed drug (composition 1) was 18 intravenous infusions at a rate of 50 drops per minute. As a result of treatment, the subjective and objective state of the patient returned to normal. The patient recovered. The diagnosis is removed.

Example 2. Patient Varova M., born in 1965 Diagnosis: cytomegalovirus infection, toxoplasmosis, suffers from habitual miscarriage. The course of treatment of the proposed drug (composition 2) was 20 intravenous infusions. As a result, the normal course of pregnancy, physiological birth, a healthy baby was born.

Example 3. Patient Dyatlovskaya born in 1946 disability of group II after influenza A, tremor of the extremities. The course of treatment of the proposed drug was 20 intravenous infusions. As a result of treatment with the drug (composition 3), the condition improved, has a disability of group III, it works.

Example 4. Patient Ryzhova M., born in 1965 Diagnosis Infertility II degree, toxoplasmosis, cytomegalovirus infection. The course of treatment of the proposed drug (composition 1) was 20 intravenous infusions. As a result of treatment, the diagnosis is removed.

Example 5. Patient Permyakova N.V., 21 years old. Diagnosis: Hepatitis D. (comp). The course of treatment of the proposed drug (composition 2) was 15 intravenous infusions at a rate of 50 drops per minute after 4 days. After 1 month, the course was repeated in 5 droppers every 4 days. As a result of treatment, the subjective and objective state of the patient returned to normal. The patient recovered. The diagnosis is removed.

6. Patient Galagan L.P. 47 years old. Diagnosis: Influenza "V" (comp). The course of treatment of the proposed drug (composition 3) was 12 intravenous infusions of 200 ml at a rate of 50 drops per minute every 4 days. The result is a complete cure. The patient recovered. The diagnosis is removed.

7. Patient Petrishchenko OA 18 years. Diagnosis: Influenza "A" (comp). Treatment was carried out during the epidemic against a background of high temperature. The treatment course of the proposed drug (composition 1) was 12 intravenous infusions of 200 ml at a rate of 45 drops per minute for 3 consecutive days. The result is a complete cure. The diagnosis is removed.

Thus, the proposed tool for the treatment of hepatitis, or toxoplasmosis, or cytomegalovirus infection, or influenza is an effective potential drug, non-toxic since contains in its composition the components studied and tested in practical health care and, after further in-depth study, may find wide application in practical medicine. The method of preparation does not require sophisticated equipment and hard-to-reach preparations, which indicates the industrial applicability of the invention.

Claims (1)

An agent for the treatment of hepatitis, toxoplasmosis, cytomegavirus infection and influenza, characterized in that it is a physiological solution for intravenous administration containing hydrogen peroxide, 0.2% solution of riboxin and a decoction of licorice roots in the following ratio of ingredients, ml / l: Hydrogen peroxide 0.6-1.25 0.2% riboxin solution 25.0-50.0 Licorice root broth 5.0-10.0 Saline Up to 1000